Activation of mineralocorticoid receptors in the rostral ventrolateral medulla is involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats

被引:0
作者
Toshiaki Nakagaki
Yoshitaka Hirooka
Ryuichi Matsukawa
Masaaki Nishihara
Masatsugu Nakano
Koji Ito
Sumio Hoka
Kenji Sunagawa
机构
[1] Kyushu University Graduate School of Medical Sciences,Department of Cardiovascular Medicine
[2] Kyushu University Graduate School of Medical Sciences,Department of Anesthesiology and Critical Care Medicine
[3] Kyushu University Graduate School of Medical Sciences,Department of Advanced Cardiovascular Regulation and Therapeutics
来源
Hypertension Research | 2012年 / 35卷
关键词
blood pressure; mineralocorticoid receptor; rostral ventrolateral medulla; sympathetic nervous system;
D O I
暂无
中图分类号
学科分类号
摘要
Mineralocorticoid receptor (MR) is recognized as a target for therapeutic intervention in hypertension and heart failure. MRs in the central nervous system are thought to have an important role in blood pressure regulation. Thus, we examined whether activation of the MR pathway in the rostral ventrolateral medulla (RVLM) of the brainstem contributes to the neural mechanism of hypertension in stroke-prone spontaneously hypertensive rats (SHRSPs). We microinjected eplerenone, aldosterone or Na+-rich artificial cerebrospinal fluid (aCSF) into the RVLM of anesthetized Wistar–Kyoto (WKY) rats and SHRSPs. Arterial pressure (AP), heart rate (HR) and renal sympathetic nerve activity (RSNA) were recorded. The expressions of the MR protein and the serum- and glucocorticoid-regulated kinase protein (Sgk1), which is a marker of MR activity, in the RVLM were measured by western blot analysis. Bilateral microinjection of eplerenone into the RVLM decreased AP and RSNA in WKY rats and SHRSPs, and the decreases in those variables were significantly greater in SHRSPs than WKY rats. Microinjection of aldosterone or Na+-rich aCSF into the RVLM increased AP and RSNA dose-dependently. The increases in those variables were significantly greater in SHRSPs than in WKY rats. The pressor responses of aldosterone or Na+-rich aCSF were attenuated by the prior injection of eplerenone in SHRSPs. Sgk1 expression levels in the RVLM were significantly greater in SHRSPs than in WKY rats. These findings suggest that activation of MRs in the RVLM enhances sympathetic activity, thereby contributing to the neural mechanism of hypertension in the SHRSP.
引用
收藏
页码:470 / 476
页数:6
相关论文
共 226 条
[1]  
Esler M(2010)The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management J Appl Physiol 108 227-237
[2]  
Grassi G(2009)Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives Hypertension 54 690-697
[3]  
Guyenet PG(2006)The sympathetic control of blood pressure Nat Rev Neurosci 7 335-346
[4]  
Pitt B(2003)Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309-1321
[5]  
Remme W(2011)High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension Hypertens Res 34 74-78
[6]  
Zannad F(2004)Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats Hypertension 43 1252-1257
[7]  
Neaton J(2011)Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats Hypertens Res 34 584-591
[8]  
Martinez F(2011)Angiotensin II and aldosterone-induced neuronal damage in neurons through an astrocyte-dependent mechanism Hypertens Res 34 773-778
[9]  
Roniker B(2011)Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats Hypertens Res 34 817-824
[10]  
Bittman R(2009)Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension Hypertens Res 32 321-324